Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people

ROUCO, SANTIAGO OVIEDO; RODRIGUEZ, PAMELA E; MIGLIETTA, ESTEBAN A; RALL, PABLO; LEDESMA, MARÍA M GONZALEZ LOPEZ; VARESE, AUGUSTO; PASCUALE, CARLA A; OJEDA, DIEGO S; MAZZITELLI, BIANCA; SANCHEZ, LAUTARO; CEBALLOS, ANA; PEREZ, EDUARDO; GEFFNER, JORGE; MIRAGAYA, YANINA; ROSSI, ANDRÉS H; GAMARNIK, ANDREA V

LANCET INFECTIOUS DISEASES

ELSEVIER SCIENCE INC

Año: 2022 vol. 22 p. 1118 - 1119

1473-3099

Increased Antibody Response Induced by Heterologous Booster Against SARSCoV-2 after Virus Inactivated BBIBP-CorV Vaccination in the ElderlyWhole-virion inactivatedSARS-CoV-2 vaccines are one of the most widely used around the world. However, incontrast with the mRNA and adenovirus-based platforms, limitedinformation is available about the immune response induced by virus inactivatedvaccines andthe convenience of applying heterologous boosters to achieve a better responseagainst variants of concerns including Omicron. This lack of informationis particularly relevant in relationship to the vaccination schemes applied inthe elderly. In this study, we performed a longitudinal analysis of serumsamples from an elderly population (averaged age 79, total of 124 volunteers)obtained 21, 100, 160 and 220 days after two-dose vaccination with the virusinactivated BBIBP-CorV (Sinopharm) vaccine, and 21 days after application of a boosterwith AZD1222, Sputnik V or BNT162b2. Because of the low seroconversion ratesobserved after BBIBP-CorV primary vaccination, a homologous booster dose wasnot included in this study. We evaluated serum levels of IgG anti-spikeantibodies as well as neutralizing capacity against theoriginal B.1 lineage and the variant of concern Omicron